Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

PURPOSE: To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine. PATIENTS AND METHODS: Eligible adults (advanced solid tumor; performance status ≤ 2) received capecitabine 500mg/m(2) PO BID days 1-14 and FDR gemcitabine (...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Attia, Steven, Morgan-Meadows, Sherry, Holen, Kyle D., Bailey, Howard H., Eickhoff, Jens C., Schelman, William R., Traynor, Anne M., Mulkerin, Daniel L., Campbell, Toby C., McFarland, Thomas A., Huie, Michael S., Cleary, James F., Tevaarwerk, Amye J., Alberti, Dona B., Wilding, George, Liu, Glenn
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676212/
https://ncbi.nlm.nih.gov/pubmed/18841362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0844-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia